Cargando…

Abiraterone Acetate Complexes with Biometals: Synthesis, Characterization in Solid and Solution, and the Nature of Chemical Bonding

Abiraterone acetate (AbirAc) is the most used steroidal therapeutic agent for treatment of prostate cancer. The mainly hydrophobic molecular surface of AbirAc results in its poor solubility and plays an important role for retention of abiraterone in the cavity of the receptor formed by peptide chain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buikin, Petr, Vologzhanina, Anna, Novikov, Roman, Dorovatovskii, Pavel, Korlyukov, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535913/ https://www.ncbi.nlm.nih.gov/pubmed/37765151 http://dx.doi.org/10.3390/pharmaceutics15092180

Ejemplares similares

Abiraterone Acetate
Publicado: (2012)

Synthesis, Structure and Electrochemical Properties of Acetamide- and Caprolactam-Containing Silicon Catecholates
por: Kramarova, Eugenia P., et al.
Publicado: (2021)

N-N(+) Bond-Forming Intramolecular Cyclization of O-Tosyloxy β-Aminopropioamidoximes and Ion Exchange Reaction for the Synthesis of 2-Aminospiropyrazolilammonium Chlorides and Hexafluorophosphates
por: Kayukova, Lyudmila, et al.
Publicado: (2023)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
por: Gauthier, Hélène, et al.
Publicado: (2012)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Comparison of a new optical biometer and a standard biometer in cataract patients
por: Kongsap, Pipat
Publicado: (2016)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

Announcement: International Biometals Symposium
Publicado: (1996)

Systematic Development of Solid Lipid Nanoparticles of Abiraterone Acetate with Improved Oral Bioavailability and Anticancer Activity for Prostate Carcinoma Treatment
por: Beg, Sarwar, et al.
Publicado: (2022)

Novel Polymorph of Favipiravir—An Antiviral Medication
por: Goloveshkin, Alexander S., et al.
Publicado: (2021)

Refractive Predictability and Biometry Agreement of a Combined Swept Source Optical Coherence and Reflectometry Biometer Compared to an Optical Low Coherence Reflectometry Biometer and an SS-OCT Biometer
por: Gjerdrum, Bjørn, et al.
Publicado: (2023)

Exploitation of knowledge databases in the synthesis of zinc(II) malonates with photo-sensitive and photo-insensitive N,N′-containing linkers
por: Zorina-Tikhonova, Ekaterina N., et al.
Publicado: (2018)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Intermolecular Interactions in Crystal Structures of Imatinib-Containing Compounds
por: Vologzhanina, Anna V., et al.
Publicado: (2020)

Biometals in rare neurodegenerative disorders of childhood
por: Parker, Sarah J., et al.
Publicado: (2013)

Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
por: Acharya, M., et al.
Publicado: (2012)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2014)

Synthesis and Structure of the Bis- and Tris-Polyhedral Hybrid Carboranoclathrochelates with Functionalizing Biorelevant Substituents—The Derivatives of Propargylamine Iron(II) Clathrochelates with Terminal Triple C≡C Bond(s)
por: Zelinskii, Genrikh E., et al.
Publicado: (2021)

Axial length acquisition success rates and agreement of four optical biometers and one ultrasound biometer in eyes with dense cataracts
por: Tañá-Rivero, Pedro, et al.
Publicado: (2023)

Comparing Predictive Accuracy of a Swept Source Optical Coherence Tomography Biometer and an Optical Low Coherence Reflectometry Biometer
por: Blehm, Clayton, et al.
Publicado: (2023)

Reproducibility of the Optical Biometer OA-1000 (Tomey)
por: Goebels, Susanne Christiane, et al.
Publicado: (2014)

Distribution of manganese and other biometals in flatiron mice
por: Seo, Young Ah, et al.
Publicado: (2015)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
por: James, Aloysius, et al.
Publicado: (2018)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
por: Castellan, Pietro, et al.
Publicado: (2018)

Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report
por: Akpokavie, Dela, et al.
Publicado: (2023)

Repeatability of a fully automated swept-source optical coherence tomography biometer and agreement with a low coherence reflectometry biometer
por: Domínguez-Vicent, Alberto, et al.
Publicado: (2023)

Comparison of a new biometer using swept-source optical coherence tomography and a conventional biometer using partial coherence interferometry
por: Higashiyama, Tomoaki, et al.
Publicado: (2018)

Crystal structures of (E)-5-(4-methylphenyl)-1-(pyridin-2-yl)pent-2-en-4-yn-1-one and [3,4-bis(phenylethynyl)cyclobutane-1,2-diyl]bis(pyridin-2-ylmethanone)
por: Ushakov, Ivan E., et al.
Publicado: (2020)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
por: Poon, Darren M. C., et al.
Publicado: (2016)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
por: Rauch, Simon, et al.
Publicado: (2016)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aprqgbsup9tsnv986thg0fup9r